- RecruitingPHASE1, PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
This study looks into a new medicine, patritumab deruxtecan, for HER2-positive breast cancer that has spread and can't be removed by surgery. Researchers want to see if it's safe, how well people tolerate it, and if it can shrink or get rid of the cancer.
For: Breast Neoplasms · Breast CancerUnited States · Canada · Israel - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
For: Metastatic Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
For: HER2 Positive Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This study looks at how a drug called tucatinib, combined with trastuzumab, works for various cancers that have a specific change (alteration) in their HER2 gene. It focuses on cancers that have spread or can't be fully removed by surgery.
For: Uterine Neoplasms · Uterine Cervical Neoplasms · Biliary Tract NeoplasmsUnited States · Belgium · Germany - RecruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
For: Breast Neoplasms · Gastroesophageal Junction Adenocarcinoma · HER2 Low Breast NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
For: HER2-positive Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia